NYSEAMERICAN:OSTX OS Therapies Q3 2026 Earnings Results & Report $0.80 -0.02 (-2.12%) Closing price 11/20/2026 04:10 PM EasternExtended Trading$0.81 +0.01 (+0.87%) As of 11/20/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. OS Therapies missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.23 versus the -$0.13 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeAfter Market ClosesConference Call7:00 AM ET OS Therapies EPS ResultsActual EPS-$0.23Consensus EPS -$0.13Beat/MissMissed by -$0.10One Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) OS Therapies Q3 2026 Earnings FAQ Did OS Therapies beat earnings estimates for Q3 2026? OS Therapies (NYSEAMERICAN:OSTX) reported earnings of -$0.23 per share for Q3 2026, missing the consensus estimate of -$0.13. The report was announced on Monday, November 16, 2026. OS Therapies Earnings HeadlinesOS Therapies (NYSEAMERICAN:OSTX) Shares Climb 9.4% - Still a Buy?November 18, 2026 | americanbankingnews.comOS Therapies Notes FDA CNPV Program SuspensionNovember 12, 2026 | tipranks.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 22 at 1:00 AM | Profits Run (Ad)OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary ...November 10, 2026 | finance.yahoo.comOS Therapies Announces Warrant Offer to Extend RunwayOctober 19, 2026 | tipranks.comRubenstein Public Relations Named Agency of Record for OS TherapiesOctober 8, 2026 | globenewswire.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX) is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare bone cancer, and potentially other cancers. Its work centers on therapies intended to address the significant risk of recurrence and spread associated with the disease. The company’s lead candidate, OST-HER2, is an investigational immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. OS Therapies has studied it for osteosarcoma, including disease that has spread to the lungs. OST-HER2 remains an investigational product and is not an approved treatment. OS Therapies also describes a broader development effort aimed at advancing treatments for osteosarcoma and other solid tumors. Its activities include clinical development and research into therapies for cancers with limited treatment options.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Bargain Hunting: Why Off-Price Retail Is WinningIf NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.